Review

sirnas targeting bub1 (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress sirnas targeting bub1
Sirnas Targeting Bub1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bub1/BAY-1816032/pm42014906-101-7-17
Average 95 stars, based on 19 article reviews

sirnas targeting bub1 - by Bioz Stars, 2026-10

95/100 stars

Images

Concentration Assay:

Article Title: CENP-E initiates chromosome congression by opposing Aurora kinases to promote end-on attachments
Article Snippet: Aurora A inhibitor MLN8237 (MedChemExpress, IC 50 value 4 nM) at a final concentration of 125 nM or 250 nM as noted, was added acutely before imaging or 30–60 min before fixation. .. Bub1 inhibitor BAY-320 (MedChemExpress, IC 50 value 680 nM) at a final concentration of 10 μM, was added acutely before imaging. .. Haspin inhibitor 5-Iodotubercidin (5-ITu) (MedChemExpress, IC 50 value 5–9 nM) at a final concentration of 2 μM, was added acutely before imaging.

Imaging:

Sterility:

Article Title: Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma
Article Snippet: .. The selective BUB1 kinase inhibitor, BAY-1816032 (HY-103020, MedChemExpress), was reconstituted in DMSO (472301, Sigma Aldrich) under sterile conditions, aliquoted, and stored at −80 °C until used. .. Nonmalignant mesothelial cell line MeT-5A (CRL-9444) and MPM cell lines H2052 (NCI-H2052; CRL-5915), H2452 (NCI-H2452; CRL-5946), and H28 (NCI-H28; CRL-5820) were purchased from American Type Culture Collection (ATCC; Manassas, VA).

Article Title: Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma.
Article Snippet: .. The selective BUB1 kinase inhibitor, BAY-1816032 (HY-103020, MedChemExpress), was reconstituted in DMSO (472301, Sigma Aldrich) under sterile conditions, aliquoted, and stored at −80 °C until used. ..

other:

Article Title: BUB1 Inhibition Induces Ferroptosis in Triple-Negative Breast Cancer Cell Lines
Article Snippet: BUB1 kinase inhibitor BAY1816032 (Catalog No. HY-103020), ferroptosis inducer RSL3 (Catalog No. HY-100218A), and ferroptosis inhibitor Ferrostatin-1 (Catalog No. HY-100579) were obtained from MedChemExpress (Monmouth Junction, NJ, USA).

Transfection:

Article Title: BUB1 as a candidate non-oncogene addiction vulnerability in metastatic phaeochromocytoma/paraganglioma.
Article Snippet: .. After 4–6 h, cells were transfected with siRNAs targeting BUB1 or treated with varying concentrations of BAY1816032 (MedChemExpress). ..

Image Search Results

Journal: Scientific Reports

Article Title: BUB1 promotes cell stem-like properties and serves as a diagnostic biomarker for lung cancer

doi: 10.1038/s41598-026-38997-4

Figure Lengend Snippet: Expression profile of BUB1 in lung cancer. ( A ) BUB1 mRNA expression across various cancer types from the GEPIA database, with LUAD and LUSC highlighted in blue. ( B , C ) BUB1 mRNA expression in non-paired ( B ) and paired tumor tissues ( C ) in TCGA-LUAD dataset.( D , E ) BUB1 mRNA expression in non-paired ( D ) and paired tumor tissues ( E ) in TCGA-LUSC dataset. ( F , G ) BUB1 mRNA expression in non-paired tumor tissues in the GSE31210 dataset ( G ) and paired tumor tissues in the GSE75037 dataset ( G ) for LUAD. ( H , I ) BUB1 mRNA expression in non-paired tumor tissues in the GSE33532 ( H ) and paired tumor tissues in the GSE134381 dataset ( G ) for LUSC. * P < 0.05, *** P < 0.001.

Article Snippet: For IL-17 pathway inhibition studies, cells were co-treated with 1:200 diluted neutrilizing IL-17C antibody (Abclonal, Wuhan, China) and BUB1 siRNA (50 nM) in serum-free medium for 48 h. Following treatments, cells were harvested for protein extraction using RIPA buffer and applied for Western blot anlaysis after determined by BCA assay.

Techniques: Expressing

Diagnostic and prognostic value of BUB1 in lung cancer. ( A ) RT-qPCR validation of BUB1 mRNA expression in paired clinical specimens ( n = 30, tumor vs. adjacent normal tissues) from the First Affiliated Hospital of Dalian Medical University. Data normalized to GAPDH and presented as mean ± SD. ( B ) Representative immunohistochemical staining (400× magnification, scale bar = 50 μm) and quantitative H-score analysis of BUB1 protein levels in clinical FFPE tumor tissues acquired from the First Affiliated Hospital of Dalian Medical University, with statistical analysis shown. ( C ) ROC curve analysis of BUB1’s diagnostic performance in clinical lung cancer tissues based on RT-qPCR data, with optimal cutoff determined by Youden’s index. ( D – F ) ROC curve analysis for BUB1’s diagnostic value in LUAD using public in silico datasets of TCGA-LUAD ( D ), GSE31210 ( E ) and GSE75037 ( F ). ( G – I ) ROC curve analysis for BUB1’s detection value in LUSC based on public datasets of TCGA-LUSC ( G ), GSE33532 ( H ) and GSE134381 ( I ). ( J , K ) Kaplan-Meier survival curves showing BUB1’s prognostic value for overall survival (OS) and relapse free survival (RFS) in LUAD ( GSE13213 and GSE31210 ) (J) and LUSC ( GSE17710 ) (K) patients from the PrognoScan database. ( L , N ) uniCox regression analysis of BUB1’s prognostic significance in LUAD ( L ) and LUSC ( N ). (M , O ) multiCox regression analysis of BUB1’s independent prognostic value for LUAD ( M ) and LUSC ( O ) after controlling for age, gender, stage and TN stages. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Scientific Reports

Article Title: BUB1 promotes cell stem-like properties and serves as a diagnostic biomarker for lung cancer

doi: 10.1038/s41598-026-38997-4

Figure Lengend Snippet: Diagnostic and prognostic value of BUB1 in lung cancer. ( A ) RT-qPCR validation of BUB1 mRNA expression in paired clinical specimens ( n = 30, tumor vs. adjacent normal tissues) from the First Affiliated Hospital of Dalian Medical University. Data normalized to GAPDH and presented as mean ± SD. ( B ) Representative immunohistochemical staining (400× magnification, scale bar = 50 μm) and quantitative H-score analysis of BUB1 protein levels in clinical FFPE tumor tissues acquired from the First Affiliated Hospital of Dalian Medical University, with statistical analysis shown. ( C ) ROC curve analysis of BUB1’s diagnostic performance in clinical lung cancer tissues based on RT-qPCR data, with optimal cutoff determined by Youden’s index. ( D – F ) ROC curve analysis for BUB1’s diagnostic value in LUAD using public in silico datasets of TCGA-LUAD ( D ), GSE31210 ( E ) and GSE75037 ( F ). ( G – I ) ROC curve analysis for BUB1’s detection value in LUSC based on public datasets of TCGA-LUSC ( G ), GSE33532 ( H ) and GSE134381 ( I ). ( J , K ) Kaplan-Meier survival curves showing BUB1’s prognostic value for overall survival (OS) and relapse free survival (RFS) in LUAD ( GSE13213 and GSE31210 ) (J) and LUSC ( GSE17710 ) (K) patients from the PrognoScan database. ( L , N ) uniCox regression analysis of BUB1’s prognostic significance in LUAD ( L ) and LUSC ( N ). (M , O ) multiCox regression analysis of BUB1’s independent prognostic value for LUAD ( M ) and LUSC ( O ) after controlling for age, gender, stage and TN stages. * P < 0.05, ** P < 0.01, *** P < 0.001.

Techniques: Diagnostic Assay, Quantitative RT-PCR, Biomarker Discovery, Expressing, Immunohistochemical staining, Staining, In Silico

BUB1 knockdown suppressed stem-like features in lung cancer cells. ( A , B ) RT-qPCR validation of BUB1 knockdown efficiency in A549 ( A ) and H226 ( B ) cells 48 h post-transfection with three independent BUB1 siRNAs. ( C ) Representative Western blot showing BUB1 protein levels 48 h post-siRNA transfection, with β-actin as loading control. The presented blots were representative of at least three independent experiments. ( D ) Sphere formation assay demonstrating reduced tumor sphere number and diameter following BUB1 knockdown (Scale bar =100 μm). ( E , F ) RT-qPCR analysis of stemness markers (EpCAM, MSI1, BMI1, Sox2) in A549 ( E ) and H226 ( F ) cells after BUB1 knockdown. ( G ) Western blot analysis of stemness markers 48 h post-BUB1 knockdown, with β-actin as loading control. The presented blots were representative of at least three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Scientific Reports

Article Title: BUB1 promotes cell stem-like properties and serves as a diagnostic biomarker for lung cancer

doi: 10.1038/s41598-026-38997-4

Figure Lengend Snippet: BUB1 knockdown suppressed stem-like features in lung cancer cells. ( A , B ) RT-qPCR validation of BUB1 knockdown efficiency in A549 ( A ) and H226 ( B ) cells 48 h post-transfection with three independent BUB1 siRNAs. ( C ) Representative Western blot showing BUB1 protein levels 48 h post-siRNA transfection, with β-actin as loading control. The presented blots were representative of at least three independent experiments. ( D ) Sphere formation assay demonstrating reduced tumor sphere number and diameter following BUB1 knockdown (Scale bar =100 μm). ( E , F ) RT-qPCR analysis of stemness markers (EpCAM, MSI1, BMI1, Sox2) in A549 ( E ) and H226 ( F ) cells after BUB1 knockdown. ( G ) Western blot analysis of stemness markers 48 h post-BUB1 knockdown, with β-actin as loading control. The presented blots were representative of at least three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Techniques: Knockdown, Quantitative RT-PCR, Biomarker Discovery, Transfection, Western Blot, Control, Tube Formation Assay

Association between BUB1 expression and immune infiltration in lung cancer by using TCGA datasets. ( A , B ) Comparison of immune cell infiltration levels between low- and high-BUB1 groups in TCGA-LUAD ( A ) and TCGA-LUSC ( B ) cohorts. ( C , D ) Pearson correlation analysis between BUB1 expression and relative abundance of 22 immune cell types in TCGA-LUAD ( C ) and TCGA-LUSC ( D ) datasets. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Scientific Reports

Article Title: BUB1 promotes cell stem-like properties and serves as a diagnostic biomarker for lung cancer

doi: 10.1038/s41598-026-38997-4

Figure Lengend Snippet: Association between BUB1 expression and immune infiltration in lung cancer by using TCGA datasets. ( A , B ) Comparison of immune cell infiltration levels between low- and high-BUB1 groups in TCGA-LUAD ( A ) and TCGA-LUSC ( B ) cohorts. ( C , D ) Pearson correlation analysis between BUB1 expression and relative abundance of 22 immune cell types in TCGA-LUAD ( C ) and TCGA-LUSC ( D ) datasets. * P < 0.05, ** P < 0.01, *** P < 0.001.

Techniques: Expressing, Comparison

BUB1 suppressed stem-like properties in lung cancer cells through IL-17 signaling pathway. ( A , B ) RT-qPCR analysis of IL-17C and IL-17RE expression in A549 ( A ) and H226 ( B ) cells 48 h post-BUB1 knockdown. ( C ) Representative Western blot showing IL-17C and IL-17RE protein levels 48 h post-BUB1 knockdown, with β-actin as loading control. The presented blots were representative of at least three independent experiments. ( D ) Sphere formation assay demonstrating alterations in stem-like features following BUB1 knockdown or combined stimulation with anti-IL17C. ( E ) Western blot analysis of stemness markers following BUB1 knockdown or combined anti-IL17C blockade. The presented blots were representative of at least three independent experiments. ** P < 0.01, *** P < 0.001.

Journal: Scientific Reports

Article Title: BUB1 promotes cell stem-like properties and serves as a diagnostic biomarker for lung cancer

doi: 10.1038/s41598-026-38997-4

Figure Lengend Snippet: BUB1 suppressed stem-like properties in lung cancer cells through IL-17 signaling pathway. ( A , B ) RT-qPCR analysis of IL-17C and IL-17RE expression in A549 ( A ) and H226 ( B ) cells 48 h post-BUB1 knockdown. ( C ) Representative Western blot showing IL-17C and IL-17RE protein levels 48 h post-BUB1 knockdown, with β-actin as loading control. The presented blots were representative of at least three independent experiments. ( D ) Sphere formation assay demonstrating alterations in stem-like features following BUB1 knockdown or combined stimulation with anti-IL17C. ( E ) Western blot analysis of stemness markers following BUB1 knockdown or combined anti-IL17C blockade. The presented blots were representative of at least three independent experiments. ** P < 0.01, *** P < 0.001.

Techniques: Quantitative RT-PCR, Expressing, Knockdown, Western Blot, Control, Tube Formation Assay

Drug screening identified BUB1-targeting compounds. ( A – C ) Three-dimensional molecular structures of candidate drugs predicted to bind to BUB1 in lung cancer. ( D – F ) Molecular docking analysis showing binding patterns between BUB1 and quercetin ( D ), cryptolepine ( E ) and etoposide ( F ).

Journal: Scientific Reports

Article Title: BUB1 promotes cell stem-like properties and serves as a diagnostic biomarker for lung cancer

doi: 10.1038/s41598-026-38997-4

Figure Lengend Snippet: Drug screening identified BUB1-targeting compounds. ( A – C ) Three-dimensional molecular structures of candidate drugs predicted to bind to BUB1 in lung cancer. ( D – F ) Molecular docking analysis showing binding patterns between BUB1 and quercetin ( D ), cryptolepine ( E ) and etoposide ( F ).

Techniques: Drug discovery, Binding Assay

FOXM1 promotes BUB1 expression at transcriptional level. (A) Venn diagram of overlapping genes identified by RNA-seq and FOXM1 PPI network. (B) Analysis the association between key gene expression and HCC patient survival. (C) The expression of BUB1 between HCC tissues and adjacent tissues from clinical patients analyzed by IHC. (D) IHC scores of BUB1 between HCC tissues and adjacent tissues from clinical patients. (E) Correlation analysis of BUB1 and Ki-67 IHC scores in tumor tissues of patients with HCC. (F) Correlation analysis of BUB1 and FOXM1 IHC scores in tumor tissues of patients with HCC. (G) Co-IP analysis of the interaction between FOXM1 and BUB1 in HUH7 cells. (H) Effects of FOXM1 shRNA and BUB1 shRNA on the expression of FOXM1 and BUB1 analyzed by Q-PCR. (I) The expression of FOXM1 and BUB1 analyzed by Western blot. (J) ChIP-qPCR analysis of the binding of FOXM1 and BUB1 promoter in HUH7 cells. (K) The sequences at the -293 bp of the BUB1-WT promoter and the BUB1-Mut promoter. (L) The binding of FOXM1 and BUB1 promoter at the -293 bp sequence GTAAACC analyzed by dual luciferase reporter assay. (M) Q-PCR analysis of BUB1 expression in different HCC cells. (N) Western blot analysis of BUB1 expression in different HCC cells. (O) KEGG pathway enrichment analysis of top 50 targets in the PPI network of BUB1. (P) Venn diagram of overlapping genes identified by RNA-seq, FOXM1 PPI network, and BUB1 PPI network. (Q) correlation analysis of BUB1 expression and LIHC cell stemness in TCGA. (R) Effect of BUB1 on the inhibitory role of FOXM1 shRNA in the proliferation of HUH7 cells. (S) Effects of BUB1 on the inhibition of FOXM1 shRNA in HUH7 colony formation. (T) Effects of BUB1 on the promotion of FOXM1 shRNA in HUH7 cell apoptosis. (U) Effects of BUB1 shRNA on HUH7 xenograft tumor volumes. (V) Photos of HUH7 xenograft tumors in each group. (W) Effects of BUB1 shRNA on HUH7 xenograft tumor weight. (X) Effects of BUB1 shRNA on Ki-67 and BUB1 expression in each group. Images were randomly selected from five replicates. Data from three independent experiments were analyzed by one-way ANOVA: * P<0.05, ** P<0.01 vs. NC KD group, # P < 0.05, ## P < 0.01 vs. FOXM1 KD group.

Journal: International Journal of Biological Sciences

Article Title: Mechanistic Insights into the FOXM1/BUB1 axis-Mediated Oncogenic Signaling in Hepatocellular Carcinoma

doi: 10.7150/ijbs.125454

Figure Lengend Snippet: FOXM1 promotes BUB1 expression at transcriptional level. (A) Venn diagram of overlapping genes identified by RNA-seq and FOXM1 PPI network. (B) Analysis the association between key gene expression and HCC patient survival. (C) The expression of BUB1 between HCC tissues and adjacent tissues from clinical patients analyzed by IHC. (D) IHC scores of BUB1 between HCC tissues and adjacent tissues from clinical patients. (E) Correlation analysis of BUB1 and Ki-67 IHC scores in tumor tissues of patients with HCC. (F) Correlation analysis of BUB1 and FOXM1 IHC scores in tumor tissues of patients with HCC. (G) Co-IP analysis of the interaction between FOXM1 and BUB1 in HUH7 cells. (H) Effects of FOXM1 shRNA and BUB1 shRNA on the expression of FOXM1 and BUB1 analyzed by Q-PCR. (I) The expression of FOXM1 and BUB1 analyzed by Western blot. (J) ChIP-qPCR analysis of the binding of FOXM1 and BUB1 promoter in HUH7 cells. (K) The sequences at the -293 bp of the BUB1-WT promoter and the BUB1-Mut promoter. (L) The binding of FOXM1 and BUB1 promoter at the -293 bp sequence GTAAACC analyzed by dual luciferase reporter assay. (M) Q-PCR analysis of BUB1 expression in different HCC cells. (N) Western blot analysis of BUB1 expression in different HCC cells. (O) KEGG pathway enrichment analysis of top 50 targets in the PPI network of BUB1. (P) Venn diagram of overlapping genes identified by RNA-seq, FOXM1 PPI network, and BUB1 PPI network. (Q) correlation analysis of BUB1 expression and LIHC cell stemness in TCGA. (R) Effect of BUB1 on the inhibitory role of FOXM1 shRNA in the proliferation of HUH7 cells. (S) Effects of BUB1 on the inhibition of FOXM1 shRNA in HUH7 colony formation. (T) Effects of BUB1 on the promotion of FOXM1 shRNA in HUH7 cell apoptosis. (U) Effects of BUB1 shRNA on HUH7 xenograft tumor volumes. (V) Photos of HUH7 xenograft tumors in each group. (W) Effects of BUB1 shRNA on HUH7 xenograft tumor weight. (X) Effects of BUB1 shRNA on Ki-67 and BUB1 expression in each group. Images were randomly selected from five replicates. Data from three independent experiments were analyzed by one-way ANOVA: * P<0.05, ** P<0.01 vs. NC KD group, # P < 0.05, ## P < 0.01 vs. FOXM1 KD group.

Article Snippet: Lentiviral recombination vectors encoding human FOXM1 complete DNA (FOXM1 cDNA) (pGV341-cFOXM1), human BUB1 complete DNA (BUB1 cDNA) (pGV341-cBUB1), empty vector control (pGV341-cNC), lentiviral shRNA vectors targeting FOXM1 (pGV112-shFOXM1), BUB1 (pGV112-shBUB1), and scrambled control (pGV112-shNC) were constructed and purchased from Genechem Co. Ltd. (Shanghai, China).

Techniques: Expressing, RNA Sequencing, Gene Expression, Co-Immunoprecipitation Assay, shRNA, Western Blot, ChIP-qPCR, Binding Assay, Sequencing, Luciferase, Reporter Assay, Inhibition

Inhibition of BUB1 suppresses HCC cell DNA repair, stemness, invasion, and migration. (A) Effects of BUB1 on DNA damage analyzed by comet assay. (B) Effects of BUB1 on γH2AX expression analyzed by IF. (C) Effects of BUB1 on the expression of DNA repair-related genes analyzed by Q-PCR. (D) Effects of BUB1 on cell cycle progression analyzed by flow cytometry. (E) Percentage of cell cycle at G0/G1, S, and G2/M phases. (F) Effects of BUB1 on the expression of cell cycle-related genes analyzed by Q-PCR. (G) Effects of BUB1 on CD44 expression in HUH7 cells analyzed by IF. (H) Effects of BUB1 on stemness-related gene expression in HUH7 cells analyzed by Q-PCR. (I) Effects of BUB1 on HUH7 cell invasion and migration. (J) Effects of BUB1 on HUH7 cell invasion and migration. Images were randomly selected from five replicates. Data from three independent experiments were statistically analyzed using one-way ANOVA: * P<0.05, ** P<0.01 vs. NC KD group, # P < 0.05, ## P < 0.01 vs. BUB1 KD group.

Journal: International Journal of Biological Sciences

Article Title: Mechanistic Insights into the FOXM1/BUB1 axis-Mediated Oncogenic Signaling in Hepatocellular Carcinoma

doi: 10.7150/ijbs.125454

Figure Lengend Snippet: Inhibition of BUB1 suppresses HCC cell DNA repair, stemness, invasion, and migration. (A) Effects of BUB1 on DNA damage analyzed by comet assay. (B) Effects of BUB1 on γH2AX expression analyzed by IF. (C) Effects of BUB1 on the expression of DNA repair-related genes analyzed by Q-PCR. (D) Effects of BUB1 on cell cycle progression analyzed by flow cytometry. (E) Percentage of cell cycle at G0/G1, S, and G2/M phases. (F) Effects of BUB1 on the expression of cell cycle-related genes analyzed by Q-PCR. (G) Effects of BUB1 on CD44 expression in HUH7 cells analyzed by IF. (H) Effects of BUB1 on stemness-related gene expression in HUH7 cells analyzed by Q-PCR. (I) Effects of BUB1 on HUH7 cell invasion and migration. (J) Effects of BUB1 on HUH7 cell invasion and migration. Images were randomly selected from five replicates. Data from three independent experiments were statistically analyzed using one-way ANOVA: * P<0.05, ** P<0.01 vs. NC KD group, # P < 0.05, ## P < 0.01 vs. BUB1 KD group.

Techniques: Inhibition, Migration, Single Cell Gel Electrophoresis, Expressing, Flow Cytometry, Gene Expression

Knockdown of BUB1 enhances HCC cell sensitivity to FOXM1 inhibitor FDI-6. (A) Effect of BUB1 shRNA on FDI-6-mediated inhibition of colony formation in HUH7 cells. (B) Effect of BUB1 shRNA on FDI-6-induced apoptosis. (C) Effect of BUB1 shRNA on FDI-6-induced DNA damage. (D) Effect of BUB1 shRNA on the G2/M phase arrest caused by FDI-6. (E) Western blot analysis of BUB1 shRNA and FDI-6 effects on DNA repair-related gene expression. (F) Western blot analysis of BUB1 shRNA and FDI-6 effects on cell cycle-related gene expression. (G) IF analysis of BUB1 shRNA and FDI-6 effects on CD44 expression. (H) Western blot analysis of BUB1 shRNA and FDI-6 effects on stemness-related gene expression. (I) Effects of BUB1 shRNA on FDI-6 mediated suppression of HCC cell invasion and migration. (J) Western blot analysis of BUB1 shRNA and FDI-6 effects on EMT-related gene expression. (K) Effects of BUB1 shRNA and FDI-6 on mouse weight. (L) Effects of BUB1 shRNA and FDI-6 on tumor volume. (M) The photos of HUH7 xenograft tumors in each group. (N) Effects of BUB1 shRNA and FDI-6 on tumor weight. (O) The inhibition ratios of BUB1 shRNA and FDI-6 on tumor volume and weight. (P) IHC analysis of the effects of BUB1 shRNA and FDI-6 on Ki-67 and FOXM1 expression Images were randomly selected from five replicates. Data from three independent experiments were statistically analyzed using one-way ANOVA: * P<0.05, ** P<0.01 vs. NC KD group, # P < 0.05, ## P < 0.01 vs. BUB1 KD+FDI-6 group.

Journal: International Journal of Biological Sciences

Article Title: Mechanistic Insights into the FOXM1/BUB1 axis-Mediated Oncogenic Signaling in Hepatocellular Carcinoma

doi: 10.7150/ijbs.125454

Figure Lengend Snippet: Knockdown of BUB1 enhances HCC cell sensitivity to FOXM1 inhibitor FDI-6. (A) Effect of BUB1 shRNA on FDI-6-mediated inhibition of colony formation in HUH7 cells. (B) Effect of BUB1 shRNA on FDI-6-induced apoptosis. (C) Effect of BUB1 shRNA on FDI-6-induced DNA damage. (D) Effect of BUB1 shRNA on the G2/M phase arrest caused by FDI-6. (E) Western blot analysis of BUB1 shRNA and FDI-6 effects on DNA repair-related gene expression. (F) Western blot analysis of BUB1 shRNA and FDI-6 effects on cell cycle-related gene expression. (G) IF analysis of BUB1 shRNA and FDI-6 effects on CD44 expression. (H) Western blot analysis of BUB1 shRNA and FDI-6 effects on stemness-related gene expression. (I) Effects of BUB1 shRNA on FDI-6 mediated suppression of HCC cell invasion and migration. (J) Western blot analysis of BUB1 shRNA and FDI-6 effects on EMT-related gene expression. (K) Effects of BUB1 shRNA and FDI-6 on mouse weight. (L) Effects of BUB1 shRNA and FDI-6 on tumor volume. (M) The photos of HUH7 xenograft tumors in each group. (N) Effects of BUB1 shRNA and FDI-6 on tumor weight. (O) The inhibition ratios of BUB1 shRNA and FDI-6 on tumor volume and weight. (P) IHC analysis of the effects of BUB1 shRNA and FDI-6 on Ki-67 and FOXM1 expression Images were randomly selected from five replicates. Data from three independent experiments were statistically analyzed using one-way ANOVA: * P<0.05, ** P<0.01 vs. NC KD group, # P < 0.05, ## P < 0.01 vs. BUB1 KD+FDI-6 group.

Techniques: Knockdown, shRNA, Inhibition, Western Blot, Gene Expression, Expressing, Migration

FOXM1 inhibitors and BAY synergistically inhibit proliferation of HCC cells and tumors. (A) Effect of BAY and FDI-6 on the proliferation of HUH7 cells. (B) The CI values of the combinations of BAY and FDI-6 at different concentration ratios. (C) Effect of BAY, FDI-6 and their combination on the colony formation of HUH7 cells. (D) Effect of BAY, FDI-6 and their combination on the apoptosis of HUH7 cells. (E) The CI values of the combinations of TST and FDI-6 at different concentration ratios. (F) Effect of TST, FDI-6 and their combination on the colony formation of HUH7 cells. (G) The CI values of the combinations of RCM-1 and FDI-6 at different concentration ratios. (H) Effect of RCM-1, FDI-6 and their combination on the colony formation of HUH7 cells. (I) Effect of BAY, FDI-6 and their sequential combination on tumor volume. (J) Effect of BAY, FDI-6 and their sequential combination on tumor weight. (K) The photos of HUH7 xenograft tumors in each group. (L) Acute toxicity analysis of 100 mg/kg FDI-6, 100 mg/kg BAY, and their combination in mice. (M) Effect of BAY, FDI-6 and their sequential combination on mouse weight. (N) Effect of BAY, FDI-6 and their sequential combination on the heart, liver, spleen, lung and kidney in mice. (O) Effect of BAY, FDI-6 and their sequential combination on the expression of Ki-67, FOXM1, and BUB1 in HUH7 xenograft tumors. Images were randomly selected from five replicates. Data from three independent experiments were statistically analyzed using one-way ANOVA: * P<0.05, ** P<0.01 vs. control group, # P < 0.05, ## P < 0.01 vs. BAY-FDI-6 group.

Journal: International Journal of Biological Sciences

Article Title: Mechanistic Insights into the FOXM1/BUB1 axis-Mediated Oncogenic Signaling in Hepatocellular Carcinoma

doi: 10.7150/ijbs.125454

Figure Lengend Snippet: FOXM1 inhibitors and BAY synergistically inhibit proliferation of HCC cells and tumors. (A) Effect of BAY and FDI-6 on the proliferation of HUH7 cells. (B) The CI values of the combinations of BAY and FDI-6 at different concentration ratios. (C) Effect of BAY, FDI-6 and their combination on the colony formation of HUH7 cells. (D) Effect of BAY, FDI-6 and their combination on the apoptosis of HUH7 cells. (E) The CI values of the combinations of TST and FDI-6 at different concentration ratios. (F) Effect of TST, FDI-6 and their combination on the colony formation of HUH7 cells. (G) The CI values of the combinations of RCM-1 and FDI-6 at different concentration ratios. (H) Effect of RCM-1, FDI-6 and their combination on the colony formation of HUH7 cells. (I) Effect of BAY, FDI-6 and their sequential combination on tumor volume. (J) Effect of BAY, FDI-6 and their sequential combination on tumor weight. (K) The photos of HUH7 xenograft tumors in each group. (L) Acute toxicity analysis of 100 mg/kg FDI-6, 100 mg/kg BAY, and their combination in mice. (M) Effect of BAY, FDI-6 and their sequential combination on mouse weight. (N) Effect of BAY, FDI-6 and their sequential combination on the heart, liver, spleen, lung and kidney in mice. (O) Effect of BAY, FDI-6 and their sequential combination on the expression of Ki-67, FOXM1, and BUB1 in HUH7 xenograft tumors. Images were randomly selected from five replicates. Data from three independent experiments were statistically analyzed using one-way ANOVA: * P<0.05, ** P<0.01 vs. control group, # P < 0.05, ## P < 0.01 vs. BAY-FDI-6 group.

Techniques: Concentration Assay, Expressing, Control

FOXM1/BUB1 axis drives HCC cell DNA repair, G2/M transition, stemness, migration, and invasion. (A) Effect of BAY, FDI-6 and their combination on DNA damage in HUH7 cells. (B) Effect of BAY, FDI-6 and their combination on DNA repair-related genes in HUH7 cells analyzed by Q-PCR. (C) Effect of BAY, FDI-6 and their combination on cell cycle progression in HUH7 cells. (D) Effect of BAY, FDI-6 and their combination on cell cycle-related genes in HUH7 cells analyzed by Q-PCR. (E) Effect of BAY, FDI-6 and their combination on CD44 expression in HUH7 cells analyzed by IF. (F) Q-PCR analysis of the effects of BAY, FDI-6 and their combination on the expression of cell cycle-related genes in HUH7 cells. (G) Effect of BAY, FDI-6 and their combination on the formation of HUH7 spheres. (H) Effect of BAY, FDI-6 and their combination on the migration and invasion of HUH7 cells. (I) Q-PCR analysis of the effects of BAY, FDI-6 and their combination on the expression of EMT-related genes in HUH7 cells. (J) The molecular mechanism of the FOXM1/BUB1 axis in regulating HCC malignancy. Images were randomly selected from five replicates. Data from three independent experiments were statistically analyzed using one-way ANOVA: * P<0.05, ** P<0.01 vs. control group, # P < 0.05, ## P < 0.01 vs. BAY-FDI-6 group.

Journal: International Journal of Biological Sciences

Article Title: Mechanistic Insights into the FOXM1/BUB1 axis-Mediated Oncogenic Signaling in Hepatocellular Carcinoma

doi: 10.7150/ijbs.125454

Figure Lengend Snippet: FOXM1/BUB1 axis drives HCC cell DNA repair, G2/M transition, stemness, migration, and invasion. (A) Effect of BAY, FDI-6 and their combination on DNA damage in HUH7 cells. (B) Effect of BAY, FDI-6 and their combination on DNA repair-related genes in HUH7 cells analyzed by Q-PCR. (C) Effect of BAY, FDI-6 and their combination on cell cycle progression in HUH7 cells. (D) Effect of BAY, FDI-6 and their combination on cell cycle-related genes in HUH7 cells analyzed by Q-PCR. (E) Effect of BAY, FDI-6 and their combination on CD44 expression in HUH7 cells analyzed by IF. (F) Q-PCR analysis of the effects of BAY, FDI-6 and their combination on the expression of cell cycle-related genes in HUH7 cells. (G) Effect of BAY, FDI-6 and their combination on the formation of HUH7 spheres. (H) Effect of BAY, FDI-6 and their combination on the migration and invasion of HUH7 cells. (I) Q-PCR analysis of the effects of BAY, FDI-6 and their combination on the expression of EMT-related genes in HUH7 cells. (J) The molecular mechanism of the FOXM1/BUB1 axis in regulating HCC malignancy. Images were randomly selected from five replicates. Data from three independent experiments were statistically analyzed using one-way ANOVA: * P<0.05, ** P<0.01 vs. control group, # P < 0.05, ## P < 0.01 vs. BAY-FDI-6 group.

Techniques: Migration, Expressing, Control

Review

sirnas targeting bub1 (MedChemExpress)

Structured Review

Images

Related Articles

Concentration Assay:

Imaging:

Sterility:

other:

Transfection:

Similar Products

Image Search Results